Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention

Launched by UNIVERSITY MEDICAL CENTER HO CHI MINH CITY (UMC) · Oct 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective different types of cholesterol-lowering treatments are for patients who are undergoing a procedure called percutaneous coronary intervention (PCI), which helps open blocked arteries in the heart. The trial compares two approaches: one that focuses on lowering a specific type of protein called Apolipoprotein B, and another that targets a type of cholesterol known as LDL-cholesterol (often referred to as "bad" cholesterol). The goal is to see which method helps more patients reach their cholesterol treatment goals after one year.

To participate in this study, you need to be at least 18 years old and scheduled to have a PCI with a special type of stent called a drug-eluting stent. However, there are some important factors that might prevent someone from joining, such as being unable to provide consent, having a serious liver condition, or having a life expectancy of less than 12 months due to other health issues. If you join the trial, you can expect close monitoring and support to help you follow the treatment plan. This study is not yet recruiting participants, but it aims to provide valuable information about the best ways to lower cholesterol in heart patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged 18 years or older.
• • 2. Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
• • 3. Patients who agree to participate and provide informed consent.
• Exclusion Criteria:
• • 1. Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.
• • 2. Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.
• • 3. Liver Disease: patients with cirrhosis or significant liver dysfunction.
• • 4. Patients with contraindication to statin or other lipid-lowering therapy.
• • 5. Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).